🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The objective of the study was to generate the data necessary to determine ...
Status
Completed
Location
GSK Investigational Site
Start Date
2007-01
Trial ID
NCT01332305
Treatments Being Tested
The primary objective of this trial is to assess the maintenance of efficac...
Status
Completed
Location
Multiple Locations
Start Date
2006-04
Trial ID
NCT00311363
Treatments Being Tested
This double-blind study will evaluate the pharmacokinetics of a single dose...
Status
Completed
Location
GSK Investigational Site
Start Date
2011-08
Trial ID
NCT01476124
Treatments Being Tested
The primary objective of this trial is to assess the long-term safety and e...
Status
Completed
Location
Multiple Locations
Start Date
2006-06
Trial ID
NCT00333359
Treatments Being Tested
This study was a multi center, randomized, double blind, active and placebo...
Status
Completed
Location
GSK Investigational Site
Start Date
2007-04
Trial ID
NCT01332318
Treatments Being Tested
The purpose of this study is to determine whether gabapentin enacarbil (XP1...
Status
Completed
Location
GSK Investigational Site
Start Date
2008-03
Trial ID
NCT00643760
Treatments Being Tested
The purpose of this study is to determine whether gabapentin enacarbil (XP1...
Status
Completed
Location
GSK Investigational Site
Start Date
2008-02
Trial ID
NCT00619476
Treatments Being Tested
The purpose of this study is evaluate the difference between two doses of g...
Status
Completed
Location
GSK Investigational Site
Start Date
2008-03
Trial ID
NCT00617461
Treatments Being Tested
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, ...
Status
Completed
Location
GSK Investigational Site
Start Date
2012-06
Trial ID
NCT01668667
Treatments Being Tested